Peripheral blood-based cell signature indicates response to interstitial brachytherapy in primary liver cancer.

ABSTRACT:

Purpose

Biomarkers are essential to implement personalized therapies in cancer treatment options. As primary liver tumors are increasing and treatment is coupled to liver function and activation of systemic cells of the immune system, we investigated blood-based cells for their ability to predict response to local ablative therapy.

Methods

We analyzed peripheral blood cells in 20 patients with primary liver cancer at baseline and following brachytherapy. In addition to platelets, leukocytes, lymphocytes, monocytes, neutrophils and most common ratios PLR, LMR, NMR and NLR, we investigated T cell and NKT cell populations of 11 responders and 9 non-responders using flow cytometry.

Results

We have found a peripheral blood cell signature that differed significantly between

SUBMITTER: Kastle S 

PROVIDER: S-EPMC10423129 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature